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Atypical E2Fs inhibit tumor angiogenesis
BGMW Weijts1,2,7, B Westendorp1,7, BT Hien1, LM Martínez-López1, M Zijp1, I Thurlings1, RE Thomas1, S Schulte-Merker3,4,
WJ Bakker1,5 and A de Bruin1,6
Atypical E2F transcription factors (E2F7 and E2F8) function as key regulators of cell cycle progression and their inactivation leads to
spontaneous cancer formation in mice. However, the mechanism of the tumor suppressor functions of E2F7/8 remain obscure. In
this study we discovered that atypical E2Fs control tumor angiogenesis, one of the hallmarks of cancer. We genetically inactivated
atypical E2Fs in epithelial and mesenchymal neoplasm and analyzed blood vessel formation in three different animal models of
cancer. Tumor formation was either induced by application of 7,12-Dimethylbenz(a)anthracene/12-O-Tetradecanoylphorbol-13-
acetate or by Myc/Ras overexpression. To our surprise, atypical E2Fs suppressed tumor angiogenesis in all three cancer models,
which is in a sharp contrast to previous ﬁndings showing that atypical E2Fs promote angiogenesis during fetal development in
mice and zebraﬁsh. Real-time imaging in zebraﬁsh displayed that ﬂuorescent-labeled blood vessels showed enhanced intratumoral
branching in xenografted E2f7/8-deﬁcient neoplasms compared with E2f7/8-proﬁcient neoplasms. DLL4 expression, a key negative
inhibitor of vascular branching, was decreased in E2f7/8-deﬁcient neoplastic cells, indicating that E2F7/8 might inhibit intratumoral
vessel branching via induction of DLL4.
Oncogene (2018) 37, 271–276; doi:10.1038/onc.2017.336; published online 18 September 2017
INTRODUCTION
During development, the formation of new blood vessels
(vasculogenesis) and blood vessels derived thereof (angiogenesis)
is a tightly regulated process, resulting in a quiescent stable
vasculature composed of arterioles, venules and capillaries.1
Angiogenesis can be transiently induced from this quiescent
vasculature, for example, during wound healing.2 During tumor
development, however, angiogenesis is almost continuously
turned on, enabling tumor progression.3 The unstable, leaky and
highly unorganized tumor vasculature not only gains access to
oxygen and nutrients, but also provides a way for cancer cells to
disseminate to distal organs.2,3 In this light, angiogenic therapies
that normalize tumor vasculature have been put forward, as they
relieve tumor hypoxia and inhibit metastasis,4,5 and could also
improve the efﬁcacy of radiotherapy, chemotherapy and
immunotherapy.5
The E2F family of transcription factors consists of eight genes,
which encode proteins that are generally classiﬁed either as
activator (E2F1–E2F3) or repressor (E2F4–8).6,7 E2F factors are key
regulators of the cell cycle,6,7 and therefore suspected regulators
of human cancer. E2F ampliﬁcation, overexpression or deletion is
observed in a wide array of human cancers,8 although the exact
contribution of these events to cancer is largely unknown. Studies
in mice however point to dual roles for E2Fs in tumor
development, suggesting that the role of E2Fs in cancer may be
cell type speciﬁc, and may depend on the oncogenic
background.8
The atypical E2Fs, E2F7 and E2F8 (E2F7/8), are unique members
of the E2F family of transcription factors as they contain two
instead of one DNA binding domain, lack a Retinoblastoma and
Dimerization Partner domain, and instead form hetero- or homo-
dimers.6,9 Interestingly, although E2Fs are key regulators of the cell
cycle, embryonically lethal E2f7/8 double-knockout (DKO) mice do
not display signiﬁcant proliferative defects, but instead display
vascular defects and widespread apoptosis, demonstrating critical
functions for E2F7/8 beyond proliferation.9 Intriguingly, recent
ﬁndings suggest a role for E2F7/8 in human cancer. For example,
deregulation of E2F7/8 is observed in various cancers.8
And although E2F7/8 are classiﬁed as transcriptional repressors,
suggesting tumor suppressive functions, E2F8 was found to be
overexpressed in human lung and hepatocellular carcinoma,
and to promote tumor growth of human lung and liver cancer
cells in xenograft studies.10,11 However, recent studies from
our lab did reveal tumor suppressive roles for E2F7/8 in mouse
models of liver and skin cancer. We demonstrated that conditional
deletion of E2f7/8 in hepatocytes resulted in spontaneous
formation of hepatocellular carcinomas and loss of E2f7/8
in keratinocytes accelerated carcinogen-induced squamous cell
carcinoma formation.12,13 However, the biological mechanisms
through which E2F7/8 control tumor development are largely
unknown. As tumor angiogenesis represents one of the
hallmarks of cancer and atypical E2Fs regulate developmental
angiogenesis,9,14 here we investigated a potential role for E2F7/8
in tumor angiogenesis, utilizing mouse and zebraﬁsh models of
cancer. We discovered that cancer cell-speciﬁc loss of atypical E2Fs
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enhances tumor angiogenesis and branching of tumor blood
vessels.
RESULTS AND DISCUSSION
E2f7/8-deﬁcient skin tumors display enhanced angiogenesis
Recently, we demonstrated that keratinocyte-speciﬁc deletion of
E2f7/8 enhances tumor growth and aggressiveness in a two-stage
mouse skin carcinogenesis model.13 In this model, skin tumors
were induced in wildtype (WT) and keratinocyte-speciﬁc E2f7/8
DKO mice by painting the back skin with application of 7,12-
Dimethylbenz(a)anthracene and 12-O-Tetradecanoylphorbol-13-
acetate. To investigate if E2F7/8 regulate tumor angiogenesis in
these skin tumors, we performed immunohistochemical staining
for Factor VIII, an established marker for blood vessels, in control
and keratinocyte-speciﬁc E2f7/8 DKO papillomas. This analysis
revealed enhanced tumor angiogenesis in E2f7/8 DKO versus WT
papillomas (Figures 1a and b). A similar trend was observed in
squamous cell carcinomas (not shown). Because transcriptional
control of E2F1 is a key mechanism through which E2F7/8 regulate
developmental processes, as shown for apoptosis9 and liver
polyploidization,15 and because E2F1 itself regulates tumor
angiogenesis16–18 and its expression was increased in E2f7/8
DKO papillomas (Figure 1c), we next explored if E2F7/8 regulate
tumor vascularization in an E2F1-dependent manner. For this
purpose tumor angiogenesis was examined in E2f1/7/8 triple
knockout (TKO) papillomas. Notably, Factor VIII staining of TKO
papillomas revealed that additional deletion of E2f1 did not
signiﬁcantly change the extent of tumor angiogenesis compared
with DKO papillomas (Figures 1a and b). Therefore we conclude
that E2F7/8 regulate angiogenesis during papilloma formation
independent of E2F1, although it cannot be excluded that its loss
is compensated for by other activator E2Fs.
Recently, we showed that E2F7/8, in cooperation with HIF1,
control vascular development through direct transcriptional
stimulation of VEGFA,14 and motor neuron development through
direct transcriptional repression of NRP1.19 As VEGFA and NRP1
both regulate embryonic and tumor angiogenesis,20,21 E2F7/8 may
regulate tumor angiogenesis through transcriptional control of
these genes. Therefore we explored if Vegfa and Nrp1 mRNA levels
were deregulated in the E2f7/8 DKO papillomas. However, despite
the fact the we could conﬁrm the stimulatory role of E2f7/8 in
Vegfa expression in two primary keratinocyte cell lines in vitro
(Supplementary Figures S1a, b), Vegfa and Nrp1 mRNA levels were
not signiﬁcantly changed in E2f7/8 DKO papillomas (Figure 1c),
while the E2F7/8 repressed target E2f19 was signiﬁcantly
increased, conﬁrming functional E2f7/8 deletion (Figure 1c). These
data therefore show that E2F7/8 inhibit papilloma vascularization,
and likely do so independent of VEGFA and NRP1.
Loss of E2F7/8 in Myc/Ras-induced sarcomas promotes tumor
angiogenesis
To determine whether E2F7/8 can regulate tumor angiogenesis in
a different oncogenic setting, we transformed WT and E2f7/8 DKO
mouse embryonic ﬁbroblasts (MEFs) with the Myc and Ras
oncogenes, hereafter referred to as control MEFs and E2F7/8
DKO MEFs, respectively (Supplementary Figure S2). MEFs were
grafted subcutaneously into athymic nude mice (Figure 2a).
Microscopic analysis showed that the morphology did not differ
between control and E2f7/8 DKO sarcomas (Figure 2b). To analyze
the amount of angiogenesis within the grafts, we assessed the
inﬂux of endothelial cells (ECs) from the host into solid tumor
mass. To this end, ECs were labeled with ﬂuorescent Isolectin B4,
an EC-speciﬁc marker, and were quantiﬁed by confocal micro-
scopy. Similar to the skin cancer model, we found a marked























































































Figure 1. E2F7/8 repress tumor angiogenesis in a two-stage skin carcinogenesis model. (a) Immunohistochemical staining for Factor VIII in
wildtype (WT), E2f7/8 double knockout (DKO) or E2f7/8/1 triple knockout (TKO) papillomas. Papillomas were obtained from a previously
performed two-stage (application of 7,12-Dimethylbenz(a)anthracene/12-O-Tetradecanoylphorbol-13-acetate) skin carcinogenesis study.13
The brown staining shows factor VIII positive cells. Arrows indicate micro blood vessels (MBV) in each genetic group. (b) Quantiﬁcation of MBV
as depicted in (a). MBV were counted in 25, 21 and 13 ﬁelds in wildtype, DKO and TKO papillomas, respectively. Wildtype and DKO papillomas
were harvested from six mice, TKO from three mice. Quantiﬁed data present the average± s.e.m. (c) qPCR analysis of Nrp1a, Vegfa, E2f1, E2f7
and E2F8 mRNA levels analyzed in wildtype (n= 6) and DKO (n= 9) papillomas. Quantiﬁed data present the average± s.d. compared with the
indicated controls. **Po0.01; ***Po0.001; ns, not signiﬁcant.
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control tumors (Figures 2c and d). We also found reduced Vegfa
mRNA levels (and increased E2f1 mRNA levels) in E2f7/8 DKO
tumors (Figure 2e). From these data we conclude that E2f7/8 also
inhibit tumor angiogenesis in a xenograft model for sarcomas
driven by Myc and Ras oncogenes, and again likely do so
independent of Vegfa which levels are reduced. To test if the
enhanced tumor angiogenesis in E2f7/8 DKO tumors could result
from enhanced EC migration (inﬂux), an in vitro scratch assay was
performed.22 In this experiment we assessed the potential of
either E2f7/8 DKO and control MEFs-conditioned medium to close
a scratch made in a conﬂuent layer of human umbilical cord vein
endothelial cells (HUVECs). HUVECs cultured in E2f7/8 DKO-
conditioned medium showed a decreased closure of the scratch
compared with controls (supplementary Fig. S3a, b). Similar results
were obtained when HUVECs were replaced with WT MEFs or
mouse embryonic ECs (not shown). These data suggest that loss of
E2F7/8 does not stimulate tumor angiogenesis by enhanced
secretion of a factor that stimulates endothelial migration.
Although we previously demonstrated that genetic ablation of
E2f7/8 enhances tumor growth in a carcinogen-induced skin
cancer model,13 in this study E2f7/8 DKO MEF tumors were instead
signiﬁcantly smaller compared with controls (Figure 2f). And
although E2F7/8 are critical regulators in preventing apoptosis
in vivo,9 which could explain the reduced tumor size, quantiﬁca-
tion of terminal deoxynucleotidyl transferase dUTP nick end
labeling-positive cells revealed a comparable incidence of
apoptosis between control and E2f7/8 DKO grafts (Figure 2f).
Therefore we next tested if tumor proliferation was affected.
Strikingly, in vivo BrdU incorporation studies demonstrated a
signiﬁcant reduction in DNA replication in E2f7/8 DKO tumors,
while staining of tumor sections with the mitosis marker phospho-
histone 3 did not show differences between control and E2f7/8
DKO tumors (Figure 2f). This indicates that E2f7/8 DKO tumors
proliferate slower, which likely contributes to their reduced size.
Notably, mice deﬁcient for activator E2Fs also have a delayed cell
cycle progression.23 Importantly, although the growth rate of
E2f7/8 DKO tumors was delayed (Figure 2f), the growth of E2f7/8
DKO MEFs in vitro was not delayed (Supplementary Figure S2a-b),
arguing for a role of the tumor microenvironment. In this regard it
is interesting to mention that the subcutaneous space, in which
the MEFs are engrafted, is relatively poorly vascularized, and that
transplanted tumors depend on HIF1 for their growth in this
relatively hypoxic environment.24 And because E2F7/8 are critical
mediators of HIF functions in vivo,14,19 E2F7/8 may be required to
support the growth of subcutaneously engrafted, hypoxic tumors.
In response to genotoxic stress, however, E2F7/8 may limit the
growth of tumors as we observed that E2f7/8 DKO skin tumors are
larger in carcinogen-induced skin cancer.13 However, future
experiments are required to address if E2F7/8 indeed differentially
affect cellular proliferation in response to hypoxic or genotoxic
stress, and whether this occurs in a HIF1-dependent manner.
Another factor that could explain why E2f7/8 DKO papillomas are
larger,13 and transplanted E2f7/8 DKO MEFs tumors smaller than
their controls, may be the fact that E2f7/8 DKO papillomas beneﬁt
for 3 months from the increased tumor vascularization, whereas
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Figure 2. Absence of E2F7/8 in mouse xenograft tumors leads to increased tumor vascularization. (a) Schematic representation of xenograft
positions and experimental setup. MEFs were injected with a total of one million cells subcutaneously into athymic nude mice. The diameter
of the tumors was monitored every 2 days. After 8 days, when the ﬁrst tumors reached a diameter of 1 cm, all mice were euthanized and
tumors harvested. (b) Hematoxylin and eosin (H&E) staining of control and E2f7/8 DKO xenograft tumors. Dashed black line indicates tumor
border. (c) Staining and quantiﬁcation (d) of intratumoral endothelial cell (Isolectin B4) and nuclei (TO-PRO-3) of control and E2f7/8 DKO
xenograft tumors (n= 8 tumors per genotype). For each tumor, ﬁve ﬁelds (×400 magniﬁcation) were quantiﬁed. White scale bars in (c) indicate
10 μM. (e) Messenger RNA expression of Vegfa, E2f1, Cdc6 and E2f7 in harvested E2f7/8 DKO and control xenografted MEF tumors (n= 8 tumors
per genotype). Quantitative PCR analysis was used to analyze mRNA levels. Messenger RNA levels in E2f7/8 DKO tumors are depicted
compared with control tumors. (f) Quantiﬁcation (similar as in (d)) of tumor volume, in vivo BrdU incorporation, and phospho-histone 3 (PH3)-
positive and TUNEL-positive cells as determined in the outer border zone of control and E2f7/8 DKO xenograft tumors. All quantiﬁed data
present the average± s.e.m. compared with the indicated controls. *Po0,05; ***Po0,005; ns, not signiﬁcant; a.u., arbitrary units.
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Figure 3. Absence of E2f7/8 in zebraﬁsh xenograft tumors leads to increased tumor vascularization. (a) Schematic representation of xenograft
positions and experimental setup. Labeled MEFs were injected 48 h post fertilization (hpf ) in the perivitelline space on the yolk sac, ventrally
of the sub intestinal vein (SIV) and posterior of the common cardinal vein (CCV or duct of Cuvier). Grafts tend to evoke an angiogenic
response from the SIV, but frequently also from the CCV (3a’). In addition, neoplastic cells from the injection site are able to enter the
circulation via the vessels formed by tumor angiogenesis and often attach or simply get stuck in the caudal vein (CV) region (3a’’). Reprinted
with permission from Magliozzi, R. et al.31 (b) Representative images and quantiﬁcation of tumor angiogenesis and size of control (Red; DiI;
n= 10) and E2f7/8 DKO tumors (Red; DiI; n= 10) injected in Tg(ﬂi1a:gfp) zebraﬁsh. (c) Time-lapse series that shows metastasizing cell (dashed
line) from the tumor into the vasculature. Insets display metastasizing cell only. (d) Representative image and quantiﬁcation of MEFs
metastasis in the trunk region. (e) Example of extravasation of (E2F7/8 DKO) MEFs into the surrounding tissue. Abbreviations: CV, caudal vein;
CCV, common cardinal vein; hpi, hours post injection. All quantiﬁed data present the average± s.d. compared with the indicated controls in at
least three independent experiments. ***Po0.05; ns, not signiﬁcant.
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Inactivation of E2F7/8 stimulates hyperbranching of intratumoral
blood vessels and decreases DLL4 expression
To investigate the tumor angiogenesis phenotype of E2f7/8-
deﬁcient tumors in more detail, we grafted Ras/Myc transformed
control and E2f7/8 DKO MEFs into Tg(ﬂi1:eGFP) zebraﬁsh, in which
endothelial cells (ECs) are labeled green. We used this xenograft
zebraﬁsh model to monitor in real-time tumor angiogenesis, and
the dissemination and metastasis of neoplastic cells (Figure 3a).25
In line with the skin cancer and mouse xenograft tumor models,
E2f7/8 DKO MEFs grafts triggered an increased inﬂux of ECs,
quantiﬁed as the amount of GFP signal within the boundaries of
the tumor 48 h post injection (hpi) (Figure 3b). Tumor size
measurements revealed that E2f7/8 DKO MEFs grafts were
comparable to controls (Figure 3b). This is consistent with the
absence of either genotoxic and hypoxic stress in this model.
Furthermore, time-lapse imaging showed a continuous movement
of tumor cells within the graft and, in addition, cells entering EC
(GFP-positive) tube-like structures (Figure 3c, and supplementary
movie). Metastatic cells were detected throughout the ﬁsh 48 hpi,
but within the existing circulatory system and with increased
density in the caudal vein (CV, Figure 3d). However, quantiﬁcation
of the number of cells present in the CV 48 hpi showed no
difference in metastatic rate between E2f7/8 DKO compared with
control MEFs (Figure 3d). Of note, we sporadically detected cells
outside the vasculature (Figure 3e). These cells could give rise to
metastases, although we cannot exclude the possibility that these
DiI- or DiD-positive cells are macrophages that have scavenged
ﬂuorescent cell debris or phagocytized MEFs. Therefore we
conclude that the absence of E2F7/8 in this xenograft zebraﬁsh
model does not impact the dissemination of neoplastic cells, but
does enhance tumor angiogenesis, consistent with the ﬁndings
from the mouse tumor studies (Figures 1 and 2).
Enhanced tumor angiogenesis can result not only from
advanced capillary sprouting, but also from excessive vessel
branching.3 For this reason we quantiﬁed the number of
intratumoral blood vessel branching points in the zebraﬁsh
xenograft model. Notably, blood vessels in E2f7/8 DKO tumors
show an almost four times higher number of branching points
compared with control tumors (Figure 4a). As the Delta-like 4
(Dll4)-Notch pathway is a key regulator of blood vessel branching
during developmental and tumor angiogenesis,26,27 we tested
whether components of this pathway were deregulated. We
found that deletion of E2f7/8 both in vitro and in engrafted
tumors, resulted in decreased expression of the Notch ligand Dll4,
and of the Dll4/Notch1 target Hey1, however the latter did not
reach statistical signiﬁcance (Figures 4b and c). The observed
increase in tumor angiogenesis upon E2f7/8 deletion is in line with
the decreased expression of Dll4, as Dll4 is known to have a
repressive function in blood vessel branching.1 Similar to the
mouse tumor xenografts, Vegfa mRNA levels in the grafts were
reduced (data not shown).
These data suggest that E2F7/8 regulate vessel branching
through direct or indirect control of DLL4 expression. This
hypothesis is supported by the observed decrease in Dll4 mRNA
levels in cultured E2f7/8 DKO MEFs before grafting into animals
(Figure 4b), and by the observation that multiple E2Fs (E2F1/4/6)
bind the DLL4 promoter in various cell types (Supplementary
Figure S4). Direct transcriptional control of the DLL4 locus by
E2F7/8 seems unlikely as DLL4 was not identiﬁed in two recent
chromatin immunoprecipitation-seq analysis for E2F7
(supplementary Fig. S4).19,28 Although we recently identiﬁed
E2F6 as a potential E2F7/8 target,19,28 E2F6 mRNA and protein
levels were not deregulated in E2f7/8 DKO MEFs (not shown).
Therefore it is unlikely that E2F7/8 control DLL4 expression
indirectly through E2F6.
Alternatively, the induction of E2F1 upon loss of E2F7/8 may
reduce DLL4 expression through inhibition of HIF1. Namely, HIF1
has been reported to stimulate DLL4 expression,29 and to bind the
DLL4 promoter (Supplementary Figure S4), whereas our previous
data suggests competitive promoter binding between E2F1 and
HIF1α,19 and reduced HIF1α protein levels upon overexpression of
E2F1 (data not shown).
In conclusion, using three different tumor models, we have
identiﬁed E2F7/8 as inhibitors of tumor angiogenesis (Figures 1b,
2d, 3b). And although we recently reported that E2F7/8 regulate
developmental angiogenesis through transcriptional stimulation
of VEGFA in cooperation with HIF1,14 this study strongly suggests
that E2F7/8 regulate tumor angiogenesis independent of VEGFA,
as we observed reduced Vegfa mRNA levels in E2f7/8 DKO MEFs
(Supplementary Figure S2c), keratinocytes (Supplementary
Figure S1b), and in engrafted tumors (Figure 2e), whereas tumor
angiogenesis was enhanced in all three tumor models. Instead we
found that E2F7/8 affect tumor angiogenesis at least in part
through control of vessel branching, possibly through indirect
control of DLL4 expression. However, we expect that this does not
present a general mechanism of how E2F7/8 mediate tumor
angiogenesis, as Dll4 expression was not deregulated in E2f7/8-
deﬁcient mouse papillomas (Supplementary Figure S1c). E2F7/8
may therefore mediate tumor angiogenesis through multiple
mechanisms. Consistent with this notion is our previous observa-
tion that a variety of angiogenic factors are deregulated in E2f7/8-
deﬁcient mouse embryos and placentas.30 In line with the
increasing understanding of E2Fs as genetic and cellular
context-dependent factors, E2F7/8 may thus affect tumor
angiogenesis in a context-dependent manner, as previously








































































































Figure 4. Loss E2f7/8 in xenografted MEF tumors in zebraﬁsh leads
to increased intratumoral blood vessel branching. Experimental
setup similar as described in Figure 3a. (a) Representative image and
quantiﬁcation (n= 10) of hyperbranching in control and E2f7/8 DKO
tumors injected in Tg(ﬂi1a:gfp) (black color; endothelial cells).
(b) Indicated mRNA levels measured in control or E2f7/8 DKO MEFs
cultured under standard conditions using qPCR. (c) Indicated mRNA
levels measured in zebraﬁsh xenografts of control (eight tumors) or
E2f7/8 DKO MEFs (ﬁve tumors). All quantiﬁed data present the
average± s.d. compared with the indicated controls. ***Po0.05; ns,
not signiﬁcant.
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suggested for other players of the E2F pathway.30 Therefore it will
be valuable to decipher these context-dependent mechanisms via
which E2F7/8 mediate tumor angiogenesis and development, in
order to fully understand the versatile role of E2F7/8 in cancer.
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